MetaCap

Generate Biomedicines (GENB) vs GH Research (GHRS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Generate Biomedicines is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GENB-24.58%GHRS+18.05%
+113%+41%-31%
Feb 27, 20261 yearNov 20, 2026
GENB-24.58%GHRS+18.05%
+110%+40%-31%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GENB versus GHRS key metrics
MetricGENBGHRS
Share price$9.54$17.53
Market cap$1.23B$1.20B
1-day change-8.00%-5.55%
YTD return—+38.03%
1-year return—+25.08%
5-year return—-21.00%
EPS (TTM)$-2.49$-0.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-48.26M
52-week high$22.67$31.44
52-week low$9.40$12.04
Distance from 52-week high-57.92%-44.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+183.02%+144.67%
Average volume1.24M294.69K
Shares outstanding129.10M68.68M
Employees31273
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Generate Biomedicines

GENB stock →

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees

About GH Research

GHRS stock →

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

GENB vs GHRS FAQ

Which is bigger, Generate Biomedicines or GH Research?

Generate Biomedicines (GENB) is larger, with a market capitalization of $1.23B compared with $1.20B for GH Research (GHRS).

Are Generate Biomedicines and GH Research in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons